Skip to content
2000
Volume 25, Issue 19
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Introduction

Breast cancer accounts for one of the leading causes of cancer deaths in women globally. Breast cancer is characterized by molecular heterogeneity, and different patients show various responses to therapy. In addition to hormone therapies, there are targeted agents and immunotherapies, but resistance to therapy and recurrence remain a critical clinical problem for patients.

Methods

This review is aimed at presenting innovations in multi-targeted therapies against breast cancer. It also includes an understanding of the biological mechanisms in pathways of this disease in relation to these agents to address treatment failure. The molecular pathways examined are ER, HER2, EGFR, VEGFR, PI3K/AKT/mTOR, MAPK, PARP, and CDK4/6. Additionally, KAT6A is identified as a molecular target along with new clinical agents that are being reviewed, as well as combinations of strategies using molecular profiling and pathology reports.

Results

The major signaling pathways that control breast cancer progression and resistance, and/or sensitivity to therapy. KAT6A, a histone acetylase, was amplified in all of the ER+ breast cancers, suggesting that it can be used as a biomarker for assessing the effectiveness of CDK4/6 inhibitors and is an epigenetic therapeutic target in mammary cell lines. KAT6A is being developed as a selective KAT6 inhibitor; however, it seems most benefits may come from additional inhibitors of Menin, which could help overcome endocrine therapeutic resistance. We also reviewed CDK4/6 Mutations and resistance invariably associated with palbociclib, as well as immunotherapy with antibody-drug conjugate, including trastuzumab deruxtecan (DS-8201).

Discussion

Multi-pathway targeting holds promise to overcome shortcomings of current monotherapies. Due to the complexity of the breast cancer molecular landscape, we must plan for and potentially target resistance mechanisms. The use of KAT6A as a biomarker, along with the use of novel inhibitors, may help inform treatment decisions and improve outcomes. Additionally, this review has identified the need to position the surveillance and addressing of our resistance mechanisms for current therapies, like CDK4/6 inhibitors and antibody-drug conjugates, rationalized combinations.

Conclusion

The future of breast cancer therapy lies in combination strategies that are developed molecular profiling and guided by resistance biomarkers. Integrative, biomarker-driven treatment approaches will provide a rationalized and likely more effective means of treating advanced and refractory breast cancer in our effort to improve patient outcomes in a targeted and personalized approach.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575409206250918080644
2025-10-08
2026-02-27

  • From This Site

    /content/journals/mrmc/10.2174/0113895575409206250918080644
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SedetaE.T. JobreB. AvezbakiyevB. Breast cancer: Global patterns of incidence, mortality, and trends.J. Clin. Oncol.20234116_suppl105281052810.1200/JCO.2023.41.16_suppl.10528
     [Google Scholar]
  2. KhanikarD. KamalasananK. KrishnamurthyA. HazarikaM. KatakiA.C. Breast cancer.In: Fundamentals in Gynaecologic Malignancy.SingaporeSpringer Nature Singapore202213318110.1007/978‑981‑19‑5860‑1_10
     [Google Scholar]
  3. Orrantia-BorundaE. Anchondo-NuñezP. Acuña-AguilarL.E. Gómez-VallesF.O. Ramírez-ValdespinoC.A. Subtypes of Breast Cancer.In: Breast Cancer.Exon Publications2022314210.36255/exon‑publications‑breast‑cancer‑subtypes
     [Google Scholar]
  4. BurguinA. DiorioC. DurocherF. Breast cancer treatments: Updates and new challenges.J. Pers. Med.202111880810.3390/jpm11080808 34442452
     [Google Scholar]
  5. VidalM. ParéL. PratA. Molecular Classification of Breast Cancer.In: Management of Breast Diseases.ChamSpringer International Publishing201620321910.1007/978‑3‑319‑46356‑8_12
     [Google Scholar]
  6. Ensenyat-MendezM. Llinàs-AriasP. OrozcoJ.I.J. Íñiguez-MuñozS. SalomonM.P. SeséB. DiNomeM.L. MarzeseD.M. Current triple-negative breast cancer subtypes: Dissecting the most aggressive form of breast cancer.Front. Oncol.20211168147610.3389/fonc.2021.681476 34221999
     [Google Scholar]
  7. ChapdelaineA.G. SunG. Challenges and opportunities in developing targeted therapies for triple negative breast cancer.Biomolecules2023138120710.3390/biom13081207 37627272
     [Google Scholar]
  8. KellyC.M. BuzdarA.U. Using multiple targeted therapies in oncology: Considerations for use, and progress to date in breast cancer.Drugs201373650551510.1007/s40265‑013‑0044‑0 23605692
     [Google Scholar]
  9. KumarM. Precision oncology, signaling pathways reprogramming and targeted therapy: A holistic approach to molecular cancer therapeutics. ScienceOpenPreprints202410.14293/PR2199.000553.v4
     [Google Scholar]
  10. XiongN. WuH. YuZ. Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies.Front. Oncol.202414140549110.3389/fonc.2024.1405491 38863622
     [Google Scholar]
  11. DoostmohammadiA. JooyaH. GhorbanianK. GohariS. DadashpourM. Potentials and future perspectives of multi-target drugs in cancer treatment: The next generation anti-cancer agents.Cell Commun. Signal.202422122810.1186/s12964‑024‑01607‑9 38622735
     [Google Scholar]
  12. ZhangY. Targeting epidermal growth factor receptor for cancer treatment: Abolishing both kinase-dependent and kinase-independent functions of the receptor.Pharmacol. Rev.20237561218123210.1124/pharmrev.123.000906 37339882
     [Google Scholar]
  13. SankarapandianV. RajendranR.L. MirukaC.O. SivamaniP. MaranB.A.V. KrishnamoorthyR. GangadaranP. AhnB.C. A review on tyrosine kinase inhibitors for targeted breast cancer therapy.Pathol. Res. Pract.202426315560710.1016/j.prp.2024.155607 39326367
     [Google Scholar]
  14. WalterK.R. GoodmanM.L. SinghalH. HallJ.A. LiT. HolloranS.M. TrincaG.M. GibsonK.A. JinV.X. GreeneG.L. HaganC.R. Interferon-stimulated genes are transcriptionally repressed by pr in breast cancer.Mol. Cancer Res.201715101331134010.1158/1541‑7786.MCR‑17‑0180 28684637
     [Google Scholar]
  15. LeuY.W. YanP.S. FanM. JinV.X. LiuJ.C. CurranE.M. WelshonsW.V. WeiS.H. DavuluriR.V. PlassC. NephewK.P. HuangT.H.M. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.Cancer Res.200464228184819210.1158/0008‑5472.CAN‑04‑2045 15548683
     [Google Scholar]
  16. Finlay-SchultzJ. GillenA.E. BrechbuhlH.M. IvieJ.J. MatthewsS.B. JacobsenB.M. BentleyD.L. KabosP. SartoriusC.A. Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III.Cancer Res.201777184934494610.1158/0008‑5472.CAN‑16‑3541 28729413
     [Google Scholar]
  17. SchmidtS Lange, CA Role of ER, PR, IRS-1 transcriptional complexes in endocrine resistant luminal breast cancer. J. Endocr. Soc.20248Supplement_1bvae163.182410.1210/jendso/bvae163.1824
     [Google Scholar]
  18. CavallaroP.A. De SantoM. BelsitoE.L. LongobuccoC. CurcioM. MorelliC. PasquaL. LeggioA. Peptides targeting HER2-positive breast cancer cells and applications in tumor imaging and delivery of chemotherapeutics.Nanomaterials20231317247610.3390/nano13172476 37686984
     [Google Scholar]
  19. SwainS.M. ShastryM. HamiltonE. Targeting HER2-positive breast cancer: Advances and future directions.Nat. Rev. Drug Discov.202322210112610.1038/s41573‑022‑00579‑0 36344672
     [Google Scholar]
  20. RojhannezhadM. SoltaniB.M. VaseiM. GhorbanmehrN. MowlaS.J. Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells.Sci. Rep.20231311951610.1038/s41598‑023‑46460‑x 37945744
     [Google Scholar]
  21. NamiB. GhanaeianA. BlackC. WangZ. Epigenetic silencing of HER2 expression during epithelial-mesenchymal transition leads to trastuzumab resistance in breast cancer.Life202111986810.3390/life11090868 34575017
     [Google Scholar]
  22. YuanY. ZhouS. LiC. ZhangX. MaoH. ChenW. JiangX. Cascade downregulation of the her family by a dual‐targeted recombinant protein–drug conjugate to inhibit tumor growth and metastasis.Adv. Mater.20223423220155810.1002/adma.202201558 35365900
     [Google Scholar]
  23. GhoshC. XingY. CaiJ. SunY. Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2.Biochem. Biophys. Rep.20233410143610.1016/j.bbrep.2023.101436 36824069
     [Google Scholar]
  24. WidatallaS.E. KorolkovaO.Y. WhalenD.S. GoodwinJ.S. WilliamsK.P. OchiengJ. SakweA.M. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.Carcinogenesis2019408998100910.1093/carcin/bgy192 30590459
     [Google Scholar]
  25. ZhengJ. MaY. FangZ. QiY. Abstract 549: PDZK1 sensitizes TNBC cells to erlotinib via promoting c-Cbl-mediated EGFR degradation and inhibiting EGFR phosphorylation.Cancer Res.2024846_Supplement54954910.1158/1538‑7445.AM2024‑549
     [Google Scholar]
  26. HainesE. SchliengerS. ClaingA. The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.Cancer Biol. Ther.201516101535154710.1080/15384047.2015.1071737 26176330
     [Google Scholar]
  27. HuhJ.I. CalvoA. StaffordJ. CheungM. KumarR. PhilpD. KleinmanH.K. GreenJ.E. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.Oncogene200524579080010.1038/sj.onc.1208221 15592523
     [Google Scholar]
  28. YoungE. MieleL. TuckerK.B. HuangM. WellsJ. GuJ.W. SU11248, A selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.Cancer Biol. Ther.201010770371110.4161/cbt.10.7.12904 20686367
     [Google Scholar]
  29. GuJ.W. TuckerK.B. HuangM. YoungE. WellsJ. PanZ.J. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.FASEB J.201024S110.1096/fasebj.24.1_supplement.774.1
     [Google Scholar]
  30. ChienM.H. LeeL.M. HsiaoM. WeiL.H. ChenC.H. LaiT.C. HuaK.T. ChenM.W. SunC.M. KuoM.L. Inhibition of metastatic potential in breast carcinoma in vivo and in vitro through targeting VEGFRs and FGFRs.Evid. Based Complement. Alternat. Med.2013201311310.1155/2013/718380 23861711
     [Google Scholar]
  31. LazarteJ.M.S. LamangoN.S. Activation of MAP kinase pathway by polyisoprenylated cysteinyl amide inhibitors causes apoptosis and disrupts breast cancer cell invasion.Biomedicines202412347010.3390/biomedicines12030470 38540084
     [Google Scholar]
  32. ShiA. LiuL. LiS. QiB. Natural products targeting the MAPK-signaling pathway in cancer: Overview.J. Cancer Res. Clin. Oncol.20241501610.1007/s00432‑023‑05572‑7 38193944
     [Google Scholar]
  33. BaharM.E. KimH.J. KimD.R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies.Signal Transduct. Target. Ther.20238145510.1038/s41392‑023‑01705‑z 38105263
     [Google Scholar]
  34. DuS.G. ZhangH.M. JiY.X. TianY.L. WangD. ZhuK. ZhangQ.G. LiuS.P. Polyphyllin VII promotes apoptosis in breast cancer by inhibiting mapk/erk signaling pathway through downregulation of SOS1.Am. J. Chin. Med.202452388590410.1142/S0192415X24500368 38716619
     [Google Scholar]
  35. HuangJ. ZengS. XiaoY. WangX. LiH. XiangT. KongL. RenG. MAPK pathway inhibition as a rational therapeutic strategy for mir-138-5p/paqr3 dysregulation-mediated epirubicin resistance in triple-negative breast cancer.bioRxiv202110.1101/2021.02.28.433242
     [Google Scholar]
  36. KimG.E. KimN.I. LeeJ.S. ParkM.H. YoonJ.H. Reduced RKIP expression is associated with breast neoplastic progression and is correlated with poor outcomes and aberrant methylation in breast carcinoma.Appl. Immunohistochem. Mol. Morphol.201725746747410.1097/PAI.0000000000000323 26894644
     [Google Scholar]
  37. BraicuC. BuseM. BusuiocC. DrulaR. GuleiD. RadulyL. RusuA. IrimieA. AtanasovA.G. SlabyO. IonescuC. Berindan-NeagoeI. A comprehensive review on mapk: A promising therapeutic target in cancer.Cancers20191110161810.3390/cancers11101618 31652660
     [Google Scholar]
  38. HeganD.C. LuY. StachelekG.C. CrosbyM.E. BindraR.S. GlazerP.M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.Proc. Natl. Acad. Sci. USA201010752201220610.1073/pnas.0904783107 20133863
     [Google Scholar]
  39. CareyJ.P.W. KarakasC. BuiT. ChenX. VijayaraghavanS. ZhaoY. WangJ. MikuleK. LittonJ.K. HuntK.K. KeyomarsiK. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of brca status in triple-negative breast cancer.Cancer Res.201878374275710.1158/0008‑5472.CAN‑17‑1494 29180466
     [Google Scholar]
  40. McCannK.E. HurvitzS.A. Advances in the use of PARP inhibitor therapy for breast cancer.Drugs Context2018713010.7573/dic.212540 30116283
     [Google Scholar]
  41. RiosJ. PuhallaS. PARP inhibitors in breast cancer: BRCA and beyond.Oncology2011251110141025 22106552
     [Google Scholar]
  42. YuS. SiY. XuM. WangY. LiuC. BiC. SunM. SunH. Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer.J. Biol. Chem.2025301110807010.1016/j.jbc.2024.108070 39667501
     [Google Scholar]
  43. YangW.C. WeiM.F. LeeY.H. HuangC.S. KuoS.H. Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway.Transl. Oncol.20244910209210.1016/j.tranon.2024.102092 39153367
     [Google Scholar]
  44. LinC.Y. YuC.J. LiuC.Y. ChaoT.C. HuangC.C. TsengL.M. LaiJ.I. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer.Clin. Transl. Oncol.202224112120213510.1007/s12094‑022‑02881‑0 35917055
     [Google Scholar]
  45. ZhangH. JiangR. ZhuJ. SunK. HuangY. ZhouH. ZhengY. WangX. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer.Breast Cancer202431453955110.1007/s12282‑024‑01567‑5 38630392
     [Google Scholar]
  46. JiangQ. XiaoJ. HsiehY.C. KumarN.L. HanL. ZouY. LiH. The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma.Biomedicines2024127161010.3390/biomedicines12071610 39062182
     [Google Scholar]
  47. GlavianoA. FooA.S.C. LamH.Y. YapK.C.H. JacotW. JonesR.H. EngH. NairM.G. MakvandiP. GeoergerB. KulkeM.H. BairdR.D. PrabhuJ.S. CarboneD. PecoraroC. TehD.B.L. SethiG. CavalieriV. LinK.H. Javidi-SharifiN.R. ToskaE. DavidsM.S. BrownJ.R. DianaP. StebbingJ. FrumanD.A. KumarA.P. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.Mol. Cancer202322113810.1186/s12943‑023‑01827‑6 37596643
     [Google Scholar]
  48. Abu-AlghaythM.H. KhanF.R. BelaliT.M. AbalkhailA. AlshaghdaliK. NassarS.A. AlmoammarN.E. AlmasoudiH.H. HessienK.B.G. aldossari, M.; Binshaya, A.S. The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer.Pathol. Res. Pract.202425515518010.1016/j.prp.2024.155180 38330621
     [Google Scholar]
  49. ZhuK. WuY. HeP. FanY. ZhongX. ZhengH. LuoT. PI3K/AKT/mTOR-Targeted therapy for breast cancer.Cells20221116250810.3390/cells11162508 36010585
     [Google Scholar]
  50. CermaK. PiacentiniF. MoscettiL. BarboliniM. CaninoF. TornincasaA. CaggiaF. CerriS. MolinaroA. DominiciM. OmariniC. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges.Biomedicines202311110910.3390/biomedicines11010109 36672617
     [Google Scholar]
  51. BrowneI.M. OkinesA.F.C. Resistance to targeted inhibitors of the pi3k/akt/mtor pathway in advanced oestrogen-receptor-positive breast cancer.Cancers20241612225910.3390/cancers16122259 38927964
     [Google Scholar]
  52. MiricescuD. TotanA. Stanescu-SpinuI.I. BadoiuS.C. StefaniC. GreabuM. PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects.Int. J. Mol. Sci.202022117310.3390/ijms22010173 33375317
     [Google Scholar]
  53. SharmaV.R. GuptaG.K. SharmaA.K. BatraN. SharmaD.K. JoshiA. SharmaA.K. PI3K/Akt/mTOR intracellular pathway and breast cancer: Factors, mechanism and regulation.Curr. Pharm. Des.201723111633163810.2174/1381612823666161116125218 27848885
     [Google Scholar]
  54. PalanisamyG.S. VenkateshappaC. GoyalM. BarrattS.A. HearnB.R. DaginakatteG. B A.A. S S.D. Bera K. S S. Khare L. Parisian A.D. Heerding D.A. Ng R.A. Harmon C.L. Samajdar S. Ramachandra M. Myles D.C. Abstract A044: The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer.Mol. Cancer Ther.20232212_SupplA044A04410.1158/1535‑7163.TARG‑23‑A044
     [Google Scholar]
  55. CaiX. ChengX. QinL. ZhangM. QiaoJ. BavadekarS. RaoS. RenF. Abstract PO2-05-08: ISM5043, a novel, selective KAT6 inhibitor for the treatment of advanced and refractory ER+ breast cancer.Cancer Research20249_SupplementPO2PO0510.1158/1538‑7445.SABCS23‑PO2‑05‑08
     [Google Scholar]
  56. MukoharaT. ParkY.H. SommerhalderD. YonemoriK. KimS-B. KimJ.H. IwataH. YamashitaT. LaymanR.M. KimG.M. Im, S-A.; Lindeman, G.J.; Rugo, H.S.; Liyanage, M.; Homji Mishra, N.; Maity, A.; Bogg, O.; Liu, L.; Li, M.; LoRusso, P. A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.J. Clin. Oncol.20244216_suppl3006300610.1200/JCO.2024.42.16_suppl.3006
     [Google Scholar]
  57. OlsenS.N. AndersonB. HattonC. JeselsohnR. BrownM. ToskaE. ArmstrongS. Abstract PR012: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer.Mol. Cancer Ther.2024236_SupplementPR012PR01210.1158/1538‑8514.SYNTHLETH24‑PR012
     [Google Scholar]
  58. CristofanilliM. LiuL. DengS. HuangX. AndréF. LoiblS. DeMicheleA. GauthierE. LiuY. TurnerN.C. Abstract 7613: Association of KAT6A expression with clinical outcomes in previously treated HR-positive and HER2-negative metastatic breast cancer.Cancer Res.2024846_Supplement7613761310.1158/1538‑7445.AM2024‑7613
     [Google Scholar]
  59. JiangR. ZhuJ. ZhangH. YuY. DongZ. ZhouH. WangX. STAT3: Key targets of growth-promoting receptor positive breast cancer.Cancer Cell Int.202424135610.1186/s12935‑024‑03541‑9 39468521
     [Google Scholar]
  60. Present and Emerging Target Therapy for Metastatic Breast CancerJ. Cancer Res. Updates20121118
     [Google Scholar]
  61. MehtaK. HegdeM. GirisaS. VishwaR. AlqahtaniM.S. AbbasM. ShakibaeiM. SethiG. KunnumakkaraA.B. Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: Evidence from clinical trials.Mil. Med. Res.20241117610.1186/s40779‑024‑00582‑z 39668367
     [Google Scholar]
  62. RoskoskiR. Targeted and cytotoxic inhibitors used in the treatment of breast cancer.Pharmacol. Res.202421010753410.1016/j.phrs.2024.107534 39631485
     [Google Scholar]
  63. AlečkovićM. LiZ. ZhouN. QiuX. LulsegedB. FoidartP. HuangX.Y. GarzaK. ShuS. KestenN. LiR. LimK. Garrido-CastroA.C. GuerrieroJ.L. QiJ. LongH.W. PolyakK. Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer.Mol. Cancer Ther.202322111304131810.1158/1535‑7163.MCT‑23‑0303 37676980
     [Google Scholar]
  64. SambiM. HaqS. SamuelV. QorriB. HaxhoF. HillK. HarlessW. SzewczukM. Alternative therapies for metastatic breast cancer: Multimodal approach targeting tumor cell heterogeneity.Breast Cancer20179859310.2147/BCTT.S130838 28280388
     [Google Scholar]
  65. SzulcA. WoźniakM. Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment—in vitro, in vivo and clinical trials literature review.Cancers2024168148310.3390/cancers16081483 38672570
     [Google Scholar]
  66. TripleNegative Breast Cancer: Tumour Biology and Optimisation of Clinical Outcome.Journal of Angiotherapy20226310.25163/angiotherapy.638C
     [Google Scholar]
  67. ZhangJ. XiaY. ZhouX. YuH. TanY. DuY. ZhangQ. WuY. Current landscape of personalized clinical treatments for triple-negative breast cancer.Front. Pharmacol.20221397766010.3389/fphar.2022.977660 36188535
     [Google Scholar]
  68. LiY. ZhanZ. YinX. FuS. DengX. Targeted therapeutic strategies for triple-negative breast cancer.Front. Oncol.20211173153510.3389/fonc.2021.731535 34778045
     [Google Scholar]
  69. MokhtarpourK. RaziS. RezaeiN. Ferroptosis as a promising targeted therapy for triple negative breast cancer.Breast Cancer Res. Treat.2024207349751310.1007/s10549‑024‑07387‑7 38874688
     [Google Scholar]
  70. VitaleI. ShemaE. LoiS. GalluzziL. Intratumoral heterogeneity in cancer progression and response to immunotherapy.Nat. Med.202127221222410.1038/s41591‑021‑01233‑9 33574607
     [Google Scholar]
  71. Ramón y CajalS. SeséM. CapdevilaC. AasenT. De Mattos-ArrudaL. Diaz-CanoS.J. Hernández-LosaJ. CastellvíJ. Clinical implications of intratumor heterogeneity: Challenges and opportunities.J. Mol. Med.202098216117710.1007/s00109‑020‑01874‑2 31970428
     [Google Scholar]
  72. PribludaA. de la CruzC.C. JacksonE.L. Intratumoral heterogeneity: From diversity comes resistance.Clin. Cancer Res.201521132916292310.1158/1078‑0432.CCR‑14‑1213 25838394
     [Google Scholar]
  73. Dagogo-JackI. ShawA.T. Tumour heterogeneity and resistance to cancer therapies.Nat. Rev. Clin. Oncol.2018152819410.1038/nrclinonc.2017.166 29115304
     [Google Scholar]
  74. KhanS. JandrajupalliS.B. BusharaN.Z.A. RajaR.D.P. MirzaS. SharmaK. VermaR. KumarA. LohaniM. Targeting refractory triple-negative breast cancer with sacituzumab govitecan: A new era in precision medicine.Cells20241324212610.3390/cells13242126 39768216
     [Google Scholar]
  75. KellerD.M. From shotgun to Gatling Gun: Multi-barrelled approach to cancer treatment.Oncology Times UK200965171810.1097/01434893‑200905000‑00015
     [Google Scholar]
  76. PetrelliA. ValabregaG. Multitarget drugs: The present and the future of cancer therapy.Expert Opin. Pharmacother.200910458960010.1517/14656560902781907 19284362
     [Google Scholar]
  77. Şeker KaratoprakG. DumlupınarB. CelepE. Kurt CelepI. Küpeli AkkolE. Sobarzo-SánchezE. A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers.Front. Pharmacol.202415142348010.3389/fphar.2024.1423480 39364049
     [Google Scholar]
  78. CuriglianoG. CriscitielloC. Successes and limitations of targeted cancer therapy in breast cancer.Prog. Tumor Res.201441153510.1159/000355896 24727984
     [Google Scholar]
  79. Baliu-PiquéM. PandiellaA. OcanaA. Breast cancer heterogeneity and response to novel therapeutics.Cancers20201211327110.3390/cancers12113271 33167363
     [Google Scholar]
  80. JemalA. BrayF. CenterM.M. FerlayJ. WardE. FormanD. Global cancer statistics.CA Cancer J. Clin.2011612699010.3322/caac.20107 21296855
     [Google Scholar]
  81. ShipitsinM. CampbellL.L. ArganiP. WeremowiczS. Bloushtain-QimronN. YaoJ. NikolskayaT. SerebryiskayaT. BeroukhimR. HuM. HalushkaM.K. SukumarS. ParkerL.M. AndersonK.S. HarrisL.N. GarberJ.E. RichardsonA.L. SchnittS.J. NikolskyY. GelmanR.S. PolyakK. Molecular definition of breast tumor heterogeneity.Cancer Cell200711325927310.1016/j.ccr.2007.01.013 17349583
     [Google Scholar]
  82. ChambersA.F. GroomA.C. MacDonaldI.C. Dissemination and growth of cancer cells in metastatic sites.Nat. Rev. Cancer20022856357210.1038/nrc865 12154349
     [Google Scholar]
  83. ReyaT. MorrisonS.J. ClarkeM.F. WeissmanI.L. Stem cells, cancer, and cancer stem cells.Nature2001414685910511110.1038/35102167 11689955
     [Google Scholar]
  84. EylerC.E. RichJ.N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis.J. Clin. Oncol.200826172839284510.1200/JCO.2007.15.1829 18539962
     [Google Scholar]
  85. DickJ.E. Breast cancer stem cells revealed.Proc. Natl. Acad. Sci. USA200310073547354910.1073/pnas.0830967100 12657737
     [Google Scholar]
  86. CampbellL.L. PolyakK. Breast tumor heterogeneity: Cancer stem cells or clonal evolution?Cell Cycle20076192332233810.4161/cc.6.19.4914 17786053
     [Google Scholar]
  87. RyszkiewiczP. MalinowskaB. SchlickerE. Polypharmacology: New drugs in 2023–2024.Pharmacol. Rep.202577354356010.1007/s43440‑025‑00715‑8 40095348
     [Google Scholar]
  88. YangT. LiW. HuangT. ZhouJ. Antibody-drug conjugates for breast cancer treatment: Emerging agents, targets and future directions.Int. J. Mol. Sci.202324151190310.3390/ijms241511903 37569276
     [Google Scholar]
  89. ZimmermanB.S. EstevaF.J. Next-generation her2-targeted antibody–drug conjugates in breast cancer.Cancers202416480010.3390/cancers16040800
     [Google Scholar]
  90. DeA. PatelS. GowthamarajanK. Next-generation therapies for breast cancer.Functional smart nanomaterials and their theranostics approaches. MadhusudhanA. PurohitS.D. PrasadR. HusenA. SingaporeSpringer202410.1007/978‑981‑99‑6597‑7_5
     [Google Scholar]
  91. GargP. SinghalG. KulkarniP. HorneD. SalgiaR. SinghalS.S. Artificial intelligence–driven computational approaches in the development of anticancer drugs.Cancers20241622388410.3390/cancers16223884 39594838
     [Google Scholar]
  92. SinghD. SachdevaD. SinghL. Advancing breast cancer drug delivery: The transformative potential of bioinformatics and artificial intelligence.Curr. Cancer Ther. Rev.202521325426410.2174/0115733947287709240229104857
     [Google Scholar]
  93. R, N; Venkatesan, M; Chandrabose, P; Karuppiah Subbulakshmanan, NK; Krishnan, S Revolutionizing breast cancer care: The role of artificial intelligence in detection, prediction, and personalized treatment. Proceedings of the First International Conference on Science, Engineering and Technology Practices for Sustainable Development, ICSETPSD 2023, Coimbatore, Tamilnadu, India, 17th-18th November2023
     [Google Scholar]
  94. TousifMd Noumil AkhterRumana LabonnoTasnima MahmudSadia IslamMd Revolutionizing cancer therapy: The role of artificial intelligence in enhancing treatment efficacy.2023 International Conference on Information and Communication Technology for Sustainable Development (ICICT4SD) Dhaka, Bangladesh, 21-23 September 2023, pp. 89–93.10.1109/ICICT4SD59951.2023.10303570
     [Google Scholar]
  95. YuD. Application and prospects of artificial intelligence in breast cancer early diagnosis, screening, and treatment. Transact Mat Biotech.Life Sci.2024321321810.62051/5wdt5q27
     [Google Scholar]
  96. MufamadiS. NgoepeM. BattisonA. ZoselaI. Novel pharmaceutical nanomaterials to advance the current breast cancer treatment – current trends and future perspective.In: Drug and Therapy Development for Triple Negative Breast Cancer.Hoboken, New JerseyWiley202311712910.1002/9783527841165.ch7
     [Google Scholar]
  97. PatelP. VedarethinamV. KorsahM.A. DanquahM.K. JeevanandamJ. Exploring the potential of nanoparticles in the treatment of breast cancer: Current applications and future directions.Appl. Sci.2024145180910.3390/app14051809
     [Google Scholar]
  98. BasingabF. AlshahraniO. AlansariI. AlmarghalaniN. AlshelaliN. AlsaiaryA. AlharbiN. ZaherK. From pioneering discoveries to innovative therapies: A journey through the history and advancements of nanoparticles in breast cancer treatment.Breast Cancer202517275110.2147/BCTT.S501448 39867813
     [Google Scholar]
  99. WangR. KumarP. RedaM. WallstrumA.G. CrumrineN.A. NgamcherdtrakulW. YantaseeW. Nanotechnology applications in breast cancer immunotherapy.Small2023Dec230863910.1002/smll.202308639 38126905
     [Google Scholar]
  100. TranP. LeeS.E. KimD.H. PyoY.C. ParkJ.S. Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment.J. Pharm. Investig.202050326127010.1007/s40005‑019‑00459‑7
     [Google Scholar]
  101. MukherjeeD. RaikwarS. Recent update on nanocarrier(s) as the targeted therapy for breast cancer.AAPS PharmSciTech202425615310.1208/s12249‑024‑02867‑x 38961013
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575409206250918080644
Loading
Breaking Barriers in Breast Cancer: Multi-Targeted Therapeutic Insights
Mini Rev Med Chem 25, 1498 (2025); https://doi.org/10.2174/0113895575409206250918080644
/content/journals/mrmc/10.2174/0113895575409206250918080644
/content/journals/mrmc/10.2174/0113895575409206250918080644
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biomarker; Breast cancer; hormone receptors; KAT6A; multi-targeted; tyrosine kinase

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test